News Lords defy government with post-Brexit guarantee for EU nati... Peers introduce amendment to Brexit bill.
News US MCT8 deficiency patients get 1st drug as Emcitate debuts Egetis has launched the first-ever therapy for the ultra-rare disease MCT8 deficiency in the US, with a list price of $950,000 per year.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
